Collaboration platform · demo
Three parties. One resistant-cancer programme.
A drug-development team, a wet lab and a hospital work in one workspace on EGFR-mutant lung adenocarcinoma after osimertinib. Cytogent recommends the next experiments, the best-fit lab and the matching patient cohorts.
Drug Development
Neris
Next-experiment batches, lab matches and cohort evidence for NRX-417.
Vilnius, Saulėtekio al.
Sign inLaboratory
Saulėtekis BioLab
Study requests, model bank, quality and capacity for partner studies.
Vilnius, Saulėtekis Valley
Sign inHospital
Antakalnis Oncology Centre
Aggregate cohorts, data requests, governance and research impact.
Vilnius, Antakalnis
Sign in
Shared for all three portals
Collaboration Hub
The programme network, the closed loop from question to model update, and one shared thread.